Novo Nordisk raises full-year outlook on GLP-1 momentum
FROM THE WIRE · FINANCE.YAHOO.COM
Novo Nordisk A/S 4 November - Financial report for the period 1 January 2026 to 30 September 2026 Financial performance Q3 2026 adjusted and reported sales increased by 4% at CER, driven by continued GLP-1 volume growth across the US and International operations, primarily in…
Read at the source ↗MARKET IMPACTHIGH✦ News Impact agent estimateTone: expected bullishA mega-cap pharma raising full-year guidance can move the stock and the sector.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Q3 2026 adjusted operating profit rose 27% at CER.
- 02Adjusted sales grew 4% at CER, driven by GLP-1 volumes.
- 03Reported operating profit fell 9% due to DKK 8.7 billion of impairment charges.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets